Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 289

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 289
---
 Tisseel the 10 ml Tisseel kits per year at a fixed purchase price of $0.136 per unit. The payments under the Supply Agreement are         
 due 30 days from the date of invoice and the Company is subject to a service charge of 1% per month on all amounts past due.              |

The Supply Agreement had an initial term
of 3 years which ended on April 1, 2011; however, the Supply Agreement has an ever-green clause and is automatically renewable for consecutive
1 year terms unless either party gives notice of termination at least 3 months prior to the then current term. The Supply Agreement may
be terminated without cause by Baxter upon 90 days’ prior written notice to the other parties. In addition, either party may terminate
the Supply Agreement in the event of an uncured material breach or insolvency.

<div align='center'>F-37</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 9:- | COMMITMENTS AND CONTINGENCIES (Cont.) |

| 4. | In March 2019, the Company participated                                                                                           
 in the Horizon 2020 Research and Innovation Framework Programme from European Union through the EASME for its participation in    
 research and development activities of the Company. Pursuant to the participation in the Programme, the EASME will fund R&D       
 expenses up to total approved budget of approximately $2,680 (EURO 2,185 thousand), out of which $1,095 (EURO 983 thousand) was   
 received in 2019 and $1,039 (EURO 874 thousand) was received in 2021. As of December 31, 2023, the Company, recorded the amount   
 received as a grant liability in other accounts payable in balance sheets (refer to Note 4). The grant liability will be recorded 
 as reduction in research and development expenses once the Company receives approval of the project completion. Considering the   
 grantor’s entitlement to demand a complete reimbursement of the entire grant, pending the ultimate approval of the project        
 completion, the Company has not yet recognized income from this grant.                                                            
 In April 2024, the Company received the approval                                                                                  
 (refer to Note 14).                                                                                                               |

| 5. | In January 2024, the Company                                                                                                            
 renewed its facility lease agreement until December 2024. The